Biomea Fusion, Inc. 8-K

What Happened

• On April 27, 2026, Biomea Fusion, Inc. announced positive 52‑week topline results from its open‑label Phase 2 COVALENT‑112 trial of icovamenib in adults with Stage 3 Type 1 diabetes (T1D). A slide presentation was furnished with the 8‑K (Exhibit 99.1) and the company hosted a conference call/webcast to discuss the data.
• Key efficacy findings: in patients diagnosed within 0–3 years, icovamenib 200 mg once daily for 12 weeks produced a 52% increase in mean stimulated C‑peptide AUC at Week 12 (p<0.001; n=5). Mean C‑peptide AUC was largely preserved through Week 52, representing about a 7% decline from baseline after the 12‑week dosing plus 40‑week follow‑up. A dose response was observed (200 mg > 100 mg). Icovamenib was generally well tolerated with no new or unexpected safety signals through Week 52.
• Trial context: COVALENT‑112 enrolled adults 18–60 years in two cohorts (0–3 years since diagnosis, screening C‑peptide ≥0.2 nmol/L; and 3–15 years, screening C‑peptide ≥0.08 nmol/L). Patients received 12 weeks of dosing followed by 40 weeks of follow‑up. Enrollment/dosing had been interrupted by an FDA clinical hold in May 2024 that was later resolved; the reported data reflect roughly half the originally intended population and a planned placebo‑controlled Part 2 was not completed.

Key Details

• 52% increase in mean C‑peptide AUC at Week 12 for 200 mg dose in 0–3 year cohort (p<0.001; n=5).
• C‑peptide largely preserved through Week 52 after 12‑week dosing (≈7% decline from baseline).
• Dose response observed: 200 mg showed greater activity than 100 mg.
• Company plans a new Phase 2 trial (H2 2026) at four U.S. centers to test extended dosing (6–12 months at 200 mg) and evaluate adding an immunosuppressive agent.

Why It Matters

• Preserved stimulated C‑peptide over 52 weeks after only a 12‑week oral treatment is notable because published natural history in Stage 3 T1D typically shows substantial C‑peptide decline over time. That outcome could indicate a meaningful effect on residual beta‑cell function.
• For investors, the data support continued clinical development (planned Phase 2 expansion with extended dosing and combination testing) but are based on a limited, interrupted dataset (about half the planned enrollment and an open‑label design). The company will present comprehensive data at the ADA Scientific Sessions in June and has disclosed standard forward‑looking statements and risks in the 8‑K.